HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

TAK-901

an aurora B kinase inhibitor; structure in first source

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Carbolines: 283
      - TAK-901: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indole Alkaloids: 200
        Carbolines: 283
        TAK-901: 3
  - 3-Ring Heterocyclic Compounds
    - Carbolines: 283
      - TAK-901: 3
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Sulfones: 534
    - TAK-901: 3

Experts

1.	Matuszkiewicz, Jennifer: 2 articles (01/2017 - 04/2013)
2.	de Jong, Ron: 2 articles (02/2014 - 04/2013)
3.	DE Jong, Ron: 1 article (01/2017)
4.	Miya, Hiroyuki: 1 article (01/2017)
5.	Murai, Saomi: 1 article (01/2017)
6.	Okuzono, Yuumi: 1 article (01/2017)
7.	Binns, David: 1 article (02/2014)
8.	Bogatyreva, Ekaterina: 1 article (02/2014)
9.	Bradley, Daniel P: 1 article (02/2014)
10.	Cullinane, Carleen: 1 article (02/2014)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2017 - "Therefore, TAK-901 sensitizes cancer cells to BCL-xL inhibition. " 01/01/2017 - "Aurora B Inhibitor TAK-901 Synergizes with BCL-xL Inhibition by Inducing Active BAX in Cancer Cells." 04/01/2013 - "These preclinical data highlight the therapeutic potential of TAK-901, which has entered phase I clinical trials in patients within a diverse range of cancers." 04/01/2013 - "In various human cancer cell lines, TAK-901 inhibited cell proliferation with effective concentration values from 40 to 500 nmol/L. " 02/01/2014 - "Tumor growth was inhibited by 60% on day 12 of 30mg/kg TAK-901 therapy. "
2.	Polyploidy 01/01/2017 - "Polyploid cells induced by TAK-901 are vulnerable to BCL-xL inhibition. " 04/01/2013 - "Consistent with Aurora B inhibition, TAK-901 suppressed cellular histone H3 phosphorylation and induced polyploidy. "
3.	B-Cell Lymphoma (Lymphoma, B Cell) 01/01/2017 - "B-cell lymphoma-extra large (BCL-xL) depletion by siRNA or chemical inhibition synergized with TAK-901 in cancer cell lines. "
4.	Ovarian Neoplasms (Ovarian Cancer) 04/01/2013 - "In rodent xenografts, TAK-901 exhibited potent activity against multiple human solid tumor types, and complete regression was observed in the ovarian cancer A2780 model. "
5.	Leukemia 04/01/2013 - "TAK-901 also displayed potent activity against several leukemia models. "

Related Drugs and Biologics

1.	Biomarkers (Surrogate Marker)
2.	Aurora Kinase B
3.	Thymidine
4.	Glucose (Dextrose)
5.	Small Interfering RNA (siRNA)
6.	Histones (Histone)

Related Therapies and Procedures

1.	Therapeutics